- Home
- PNTG vs TSHA Comparison
PNTG vs TSHA Comparison
Compare PNTG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PNTG | TSHA |
|---|---|---|
| Founded | 2019 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PNTG | TSHA |
|---|---|---|
| Price | $29.23 | $5.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $35.33 | $10.22 |
| AVG Volume (30 Days) | 249.5K | ★ 3.7M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $847,274,000.00 | $6,310,000.00 |
| Revenue This Year | $36.69 | N/A |
| Revenue Next Year | $24.06 | N/A |
| P/E Ratio | $38.88 | ★ N/A |
| Revenue Growth | ★ 29.89 | N/A |
| 52 Week Low | $21.18 | $1.05 |
| 52 Week High | $30.46 | $6.02 |
Technical Indicators
Market Signals| Indicator | PNTG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 61.73 | 63.88 |
| Support Level | $28.99 | $5.37 |
| Resistance Level | $29.91 | $5.96 |
| Average True Range (ATR) | 0.68 | 0.30 |
| MACD | -0.14 | 0.02 |
| Stochastic Oscillator | 38.19 | 88.79 |
Price Performance
Historical ComparisonAbout PNTG The Pennant Group Inc.
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.